Business
Novo kidney trial finds Ozempic cuts cardiac risks in diabetics
Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study
April 26, 2024Your subscription includes
Unlimited Access to All Content from
The Los Angeles Post
Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study
April 26, 2024